Covaxin shows 78% overall interim efficacy, 100% efficacy against severe Covid: Bharat Biotech & ICMR
Wednesday, 21 April 2021 () Bharat Biotech's Covaxin vaccine has shown 78% interim efficacy against the coronavirus, as per the result from phase 3 trials. The vaccine has also demonstrated 100% efficacy against severe Covid-19.
Drugs Controller General of India (DCGI) on May 08 approved emergency use DRDO's anti-COVID drug which the agency said will be helpful in faster recovery of hospitalised patients. While speaking to ANI, Institute of Nuclear Medicine and Allied Sciences (INMAS-DRDO) scientists spoken about drug 2-deoxy-D-glucose (2-DG). The drug will be of immense benefit to the people suffering from COVID-19.
Amid an unprecedented surge in Covid-19 cases, some Samaritans across the Delhi-NCR region have either formed communities or taken it upon themselves to help those in distress. Of late, social media platforms have been flooded with requests for plasma donations. Adnan Shah and Sanjay Raina are two among the many who have been providing assistance to those pleading for help in the national capital region by way of a Twitter handle @PlasmaNCR. The duo claims to be resolving more than 100 plasma requirement SOS calls a day amidst a deluge of requests. Dr Sameer Kaul also joins us on the show to explain the do’s and don’ts of plasma donations.
Credit: HT Digital Content Duration: 25:57Published
In a significant directive to the states and Union Territories, the Union Health Ministry on Saturday said the requirement of a positive COVID-19 test report is not mandatory for admission to a health facility. In its revised national policy for admission of COVID patients to various dedicated health facilities, both public and private, the Union Health Ministry said no patient will be refused services on any account, including oxygen and essential drugs, even if he or she belongs to a different city. "This patient-centric measure aims to ensure a prompt, effective, and comprehensive treatment of patients suffering from COVID-19," the ministry said. Watch the full video for more details.
Credit: HT Digital Content Duration: 01:28Published
Health Minister of Chhattisgarh, TS Singh Deo on May 08 said the state government will receive 3.50 lakh doses of Covishield today and the further vaccination will go on with this. "We received 1.50 lakh Covaxin doses from Bharat Biotech on May 1 and the vaccination is going on with that. We'll receive 3.50 lakh doses of Covishield today and the vaccination will further go on with this," Deo said media persons.
Speaking on COVID-19 situation in Maharashtra, State Health Minister Rajesh Tope on May 04 said, "Few centres were closed yesterday due to doses' shortage. Got 9 lakh vials today, to last for 2-3 days. 1 lakh inoculated so far in 18-44 age groups. Order placed for 18.5 lakh vaccines (Covishield and Covaxin).
While it must be understood that taking both doses of any vaccine whether it be Covishield, Covaxin or Sputnik, the ones that are available in India, are critical, here is what we know about one dose vaccine efficiency.
#Vaccine #SingleDose #Explained
India on May 01 got the first lot of Russia's Sputnik V vaccine. The shipment arrived at the Hyderabad airport where Indian authorities received the first batch of 1.5 lakh doses of the Russia-made vaccines. India now has three vaccines - Covishield by Serum Institute of India, Covaxin by Bharat Biotech and Russia's Sputnik V. Sputnik V was given emergency use authorisation by the Indian government last month.
Bharat Biotech on Thursday announced a cut in price of its COVID-19 vaccine 'Covaxin' it plans to sell to the states to Rs 400 per dose from the earlier Rs 600. This follows a widespread criticism of..
Credit: HT Digital Content Duration: 01:25Published